- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT06807268
Een studie van het geneesmiddel genaamd Abrocitinib bij kinderen van 6 tot minder dan 12 jaar met matig tot ernstig eczeem
Een 16-weken durende, multicenter, interventionele, fase 3, gerandomiseerde, dubbelblinde, placebo-gecontroleerd, parallelle groepsstudie om de werkzaamheid en veiligheid van schouderbeurt te onderzoeken bij kinderen van 6 tot minder dan 12 jaar met matige tot ernstige atopische dermatitis
This research study is being conducted to find out if the test medicine, abrocitinib, improves eczema and is safe for children 6 to <12 years of age who have moderate-to-severe eczema. Research study participants who meet the study criteria will be assigned by chance (like the flip of a coin) to receive either abrocitinib test medicine or placebo (pretend medicine that looks just like the test medicine) for 16 weeks. The study will last for about 24 weeks in total.
Studie Overzicht
Gedetailleerde beschrijving
Different questionnaires will be used to find out how the participant's eczema is doing during the research study. An electronic diary, which looks like a cellular phone, will be used to collect the questionnaire information and other research study-related information. It will also be used to remind participants to take the test medicine each day and to fill out the questionnaires. Participants will also be asked to wear something on their wrist that looks like a children's wristwatch so we can know when they are scratching their skin because of their atopic dermatitis. Laboratory tests, physical examinations and vital signs (height, weight, temperature, blood pressure and heart rate) will be conducted before and during the research study to monitor your child's health. Participants will need to come to the clinic for research study visits and at other times during the research study, the research study doctor or nurse will call the participants to find out the participant is doing.
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Pfizer CT.gov Call Center
- Telefoonnummer: 1-800-718-1021
- E-mail: ClinicalTrials.gov_Inquiries@pfizer.com
Studie Contact Back-up
- Naam: Nancy A Sherman, BA
- Telefoonnummer: 2127332323
- E-mail: Nancy.Sherman@Pfizer.com
Studie Locaties
-
-
-
Shanghai, China, 200062
- Werving
- Shanghai Children's Hospital
-
Shanghai, China, 200092
- Werving
- Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100045
- Werving
- Beijing Children's hospital, Capital Medical University
-
-
Guangdong
-
Shenzhen, Guangdong, China, 518026
- Werving
- Shenzhen Children's Hospital
-
-
Hunan
-
Changsha, Hunan, China, 410007
- Werving
- Hunan Children's Hospital
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330000
- Werving
- Dermatology Hospital of Jiangxi Province
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, China, 200040
- Werving
- Shanghai Children's Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Werving
- Hangzhou Third People's Hospital
-
-
-
-
North Rhine-Westphalia
-
Münster, North Rhine-Westphalia, Duitsland, 48149
- Werving
- Universitätsklinikum Münster
-
-
Saxony
-
Dresden, Saxony, Duitsland, 01307
- Werving
- Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden
-
-
-
-
-
Pécs, Hongarije, 7622
- Werving
- University of Pecs
-
-
Baranya
-
Pécs, Baranya, Hongarije, 7632
- Werving
- Pécsi Tudományegyetem Klinikai Központ
-
-
Bekes County
-
Békéscsaba, Bekes County, Hongarije, 5600
- Werving
- Trial Pharma Kft.
-
-
Csongrád-csanád
-
Szeged, Csongrád-csanád, Hongarije, 6720
- Werving
- Szegedi Tudományegyetem Bőrgyógyászati és Allergológiai Klinika
-
-
Pest County
-
Budapest, Pest County, Hongarije, 1033
- Werving
- Clinexpert Kft.
-
-
-
-
-
Fukuoka, Japan, 811-1394
- Werving
- Fukuoka National Hospital
-
Fukuoka, Japan, 819-0042
- Werving
- Saruta Dermatology Clinic
-
-
Kanagawa
-
Yokohama, Kanagawa, Japan, 220-6208
- Werving
- Queen's square Medical Facilities Queen's square Dermatology and Allergology
-
-
Osaka
-
Sakai, Osaka, Japan, 593-8324
- Werving
- Dermatology and Ophthalmology Kume Clinic
-
-
Tokyo
-
Setagaya-ku, Tokyo, Japan, 157-0066
- Werving
- Sasamoto Children's Clinic
-
-
-
-
-
Chihuahua City, Mexico, 31238
- Werving
- Servicios Hospitalarios de México S.A. de C.V. (Hospital Angeles Chihuahua)
-
-
Mexico City
-
Mexico City, Mexico City, Mexico, 06720
- Werving
- Hospital Infantil de México Federico Gómez
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 64718
- Werving
- Eukarya Pharmasite S.C.
-
-
Veracruz
-
Veracruz, Veracruz, Mexico, 91900
- Werving
- Arke SMO S.A. de C.V.
-
-
-
-
Lesser Poland Voivodeship
-
Krakow, Lesser Poland Voivodeship, Polen, 30-002
- Werving
- Specjalistyczny Gabinet Dermatologiczny Aplikacyjno-Badawczy, Marek Brzewski, Paweł Brzewski spółka cywilna
-
-
Lublin Voivodeship
-
Lublin, Lublin Voivodeship, Polen, 20-573
- Werving
- LUXDERM Specjalistyczny Gabinet Dermatologiczny prof. dr hab. n. med. Dorota Krasowska
-
-
Masovian Voivodeship
-
Warsaw, Masovian Voivodeship, Polen, 02-625
- Werving
- Centrum Medyczne Evimed
-
-
Silesian Voivodeship
-
Chorzów, Silesian Voivodeship, Polen, 41-500
- Werving
- DERMAPOLIS Medical Dermatology Center dr n. med. Edyta Gebska
-
Katowice, Silesian Voivodeship, Polen, 40-611
- Werving
- Centrum Medyczne Angelius Provita
-
-
Łódź Voivodeship
-
Lodz, Łódź Voivodeship, Polen, 90-436
- Werving
- Dermoklinika - Centrum Medyczne spółka cywilna M. Kierstan, J. Narbutt, A. Lesiak
-
-
Świętokrzyskie Voivodeship
-
Ostrowiec Świętokrzyski, Świętokrzyskie Voivodeship, Polen, 27-400
- Werving
- Dermedic Jacek Zdybski
-
-
-
-
-
Zaragoza, Spanje, 50009
- Werving
- Hospital Universitario Miguel Servet
-
-
A Coruña [LA Coruña]
-
Santiago de Compostela, A Coruña [LA Coruña], Spanje, 15706
- Werving
- CHUS - Hospital Clinico Universitario
-
-
Barcelona [barcelona]
-
Granollers, Barcelona [barcelona], Spanje, 08402
- Werving
- Hospital General de Granollers
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35244
- Werving
- Cahaba Dermatology & Skin Health Center, LLC
-
-
Arkansas
-
North Little Rock, Arkansas, Verenigde Staten, 72117
- Werving
- Arkansas Research Trials
-
-
California
-
San Diego, California, Verenigde Staten, 92123
- Werving
- Investigational Drug Service - Rady Childrens Hospital-San Diego
-
San Diego, California, Verenigde Staten, 92123
- Werving
- University of California, San Diego/Rady Children's Hospital-San Diego; Pediatric & Adolescent Derm
-
-
Florida
-
Jacksonville, Florida, Verenigde Staten, 32256
- Werving
- Solutions Through Advanced Research
-
-
Idaho
-
Meridian, Idaho, Verenigde Staten, 83646
- Werving
- Ada West Research
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46250
- Werving
- Dawes Fretzin Clinical Research Group, LLC
-
-
Missouri
-
St Louis, Missouri, Verenigde Staten, 63104
- Werving
- Saint Louis University - Department of Dermatology
-
-
South Carolina
-
Charleston, South Carolina, Verenigde Staten, 29425
- Werving
- Medical University of South Carolina - South Carolina Translational Research Nexus Clinic
-
Charleston, South Carolina, Verenigde Staten, 29425
- Werving
- Medical University of South Carolina - Department of Dermatology
-
Charleston, South Carolina, Verenigde Staten, 29425
- Werving
- Medical University of South Carolina - Walton Research Building
-
Greenville, South Carolina, Verenigde Staten, 29607
- Werving
- Tribe Clinical Research, LLC
-
-
Texas
-
San Antonio, Texas, Verenigde Staten, 78235
- Werving
- Texas Dermatology and Laser Specialists
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria Children aged 6 to <12 years at the time of informed consent/assent.
• No contraception methods are required for male participants. Refer to Appendix 4 for reproductive criteria for male (Section 10.4.1) and female (Section 10.4.2) participants.
Disease Characteristics:
Participants who meet all of the following AD criteria:
- A documented diagnosis of chronic AD for at least 1 year prior to screening and confirmed at screening and baseline visits according to the Hanifin and Rajka criteria[19]; and
- A diagnosis of moderate-to-severe AD at the baseline visit (must fulfill all of the following criteria: BSA ≥10%, vIGA ≥3, EASI ≥16, and WI-NRS ≥4); and
- Documented history (within 6 months of the screening visit) of inadequate response to treatment with topical medical therapy for AD (eg, TCS and TCI), for at least 4 weeks and are candidates for systemic therapy
Other Inclusion Criteria:
Body weight ≥15 kg
Exclusion Criteria
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions:
Any medical or psychiatric condition including any active suicidal ideation in the past year or suicidal behavior in the past 5 years or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
If the participant has SDQ total score ≥17, the investigator should exclude them or refer the child to a pediatric MHP to determine if it is safe to participate in the study. A copy or summary of the evaluation should be placed in the site source documents.
Have any of the following medical conditions:
-
Infections:
- Skin infections that require treatment with systemic antimicrobials within 2 weeks prior to Day 1 (Baseline) or have superficial skin infections within 1 week of Day 1.
- History of systemic infection requiring hospitalization or parenteral antimicrobial therapy or as otherwise judged clinically significant by the investigator within 1 month prior to Day 1.
- Have a history (single episode) of disseminated herpes zoster or disseminated herpes simplex, or a recurrent localized, dermatomal herpes zoster.
- Infection with HIV, hepatitis B, and/or hepatitis C
- Evidence of active TB or inadequately treated latent TB.
-
Skin Conditions:
- Including but not limited to psoriasis, seborrheic dermatitis or lupus on Day 1 that would interfere with evaluation of AD or response to treatment.
-
Other Conditions:
- Documented history of skeletal dysplasia.
- Documented history of retinal detachment.
- History of or conditions associated with thrombocytopenia, coagulopathy or platelet dysfunction.
- Prior history of leukemia, lymphoma, sarcoma or any other malignancy.
- Immunodeficiency disorder or a first-degree relative with a hereditary immunodeficiency.
- Any other medical conditions that in the investigator's judgment make the participant inappropriate for the study.
Prior/Concomitant Therapy:
Prior treatment with a systemic JAK inhibitor for AD. Live attenuated vaccination within 6 weeks prior to Day 1 or require vaccination with live attenuated vaccines during treatment or within 6 weeks after the last dose of study intervention.
Concomitant use of strong inhibitors and inducers of CYP2C19 enzymes, strong inducers of CYP2C9 enzymes, P-gp substrates with narrow therapeutic index and sensitive CYP2C19 substrates is not allowed in the study.
Prior/Concurrent Clinical Study Experience:
Previous administration of an investigational drug within 30 days or 5 half lives, whichever is longer, of Day 1.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Abrocitinib
Abrocitinib administered as liquid oral suspension. |
Abrocitinib administered as liquid oral suspension.
Andere namen:
|
|
Placebo-vergelijker: Matching Placebo
Placebo administered as liquid oral suspension. |
Placebo administered as liquid oral suspension. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Response based on achieving Validated Investigator's Global Assessment (vIGA) score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at Week 12
Tijdsspanne: At week 12
|
The difference in proportion of responders based on vIGA at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo |
At week 12
|
|
Response based on achieving ≥75% improvement from baseline in the Eczema Area and Severity Index (EASI)-75 at Week 12
Tijdsspanne: At week 12
|
The difference in proportion of responders based on EASI-75 at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo |
At week 12
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Change from Baseline (CFB) in the Worst Itch Numerical Rating Scale (WI-NRS) at Week 2
Tijdsspanne: At week 2
|
The difference in mean CFB in WI-NRS total score at Week 2 in patients with moderate-to-severe AD treated with abrocitinib versus placebo |
At week 2
|
|
Response based on achieving at least a 4-point improvement from baseline in the WI-NRS at Week 12
Tijdsspanne: At week 12
|
The difference in proportion of responders based on achieving at least a 4-point improvement from baseline in the WI-NRS at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo |
At week 12
|
|
Response based on achieving WI-NRS <2 at Week 12
Tijdsspanne: At week 12
|
The difference in proportion of responders based on achieving WI-NRS <2 at Week 12 in patients with moderate-to-severe AD treated with abrocitinib versus placebo |
At week 12
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Pfizer CT.gov Call Center, Pfizer
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- B7451023
- 2023-509121-51-00 (Register-ID: CTIS (EU))
- 2023 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .